In Ho Jeong

In Ho Jeong

Auto-generated profile, based on publicly available information

In Ho Jeong

Department of Surgery, College of Medicine, Jeju National University, Jeju, Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
FHFarah Husain
Farah Husain
IJIn Ho Jeong
In Ho Jeong
DSDonn Spight
Donn Spight
BWBruce Wolfe
Bruce Wolfe
SMSamer G Mattar
Samer G Mattar
Husain F, et al. Ann Surg Treat Res. 2018 Aug;95(2):100-110. https://doi.org/10.4174/astr.2018.95.2.100

1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
Dong Jin KimDong Jin Kim
Dong Jin Kim
JSJeong Ho Song
Jeong Ho Song
JPJi-Hyeon Park
Ji-Hyeon Park
SKSojung Kim
Sojung Kim
SPSin Hye Park
Sin Hye Park
TAThe Information Committee of the Korean Gastric Cancer Association
The Information Committee of the Korean Gastric Cancer Association
Kim DJ, et al. J Gastric Cancer. 2024 Dec;25:e8. https://doi.org/10.5230/jgc.2025.25.e8

1 January 2013 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
SKSe Hoon Kim
Se Hoon Kim
JKJeong Jae Kim
Jeong Jae Kim
JLJeong Sub Lee
Jeong Sub Lee
SKSeung Hyoung Kim
Seung Hyoung Kim
BKBong Soo Kim
Bong Soo Kim
IJIn Ho Jeong
In Ho Jeong
Kim SH, et al. J Gastric Cancer. 2013 Sep;13(3):149-156. http://dx.doi.org/10.5230/jgc.2013.13.3.149

6 May 2024 in International Journal of Surgery
Verified
Journal Article
Open access
SPShin-Hoo Park
Shin-Hoo Park
CLChang Min Lee
Chang Min Lee
HHHoon Hur
Hoon Hur
Jae-Seok MinJae-Seok Min
Jae-Seok Min
SRSeung Wan Ryu
Seung Wan Ryu
Sungsoo ParkSungsoo Park
Sungsoo Park
JOURNAL/ijos/04.03/01279778-202408000-00031/figure1/v/2025-08-24T172537Z/r/image-jpeg Backgrounds: Strong evidence is lacking as no confirmatory randomized controlled trials (RCTs) have compared the efficacy of totally laparoscopic distal gastrectomy (TLDG) with laparoscopy-assisted distal gastrectomy (LADG). The authors performed an RCT to confirm if TLDG is different from LADG. Methods: The KLASS-07 trial is a multi-centre, open-label, parallel-group, phase III, RCT of 442 patients with clinical stage I gastric cancer. Patients were enroled from 21 cancer care centres in South Korea between January 2018 and September 2020 and randomized to undergo TLDG or LADG using blocked randomization with a 1:1 allocation ratio, stratified by the participating investigators. Patients were treated through R0 resections by TLDG or LADG as the full analysis set of the KLASS-07 trial. The primary endpoint was morbidity within postoperative day 30, and the secondary endpoint was quality of life (QoL) for 1 year. This trial is registered at ClinicalTrials.gov (NCT 03393182). Results: Four hundred forty-two patients were randomized (222 to TLDG, 220 to LADG), and 422 patients were included in the pure analysis (213 and 209, respectively). The overall complication rate did not differ between the two groups (TLDG vs. LADG: 12.2% vs. 17.2%). However, TLDG provided less postoperative ileus and pulmonary complications than LADG (0.9% vs. 5.7%, P=0.006; and 0.5% vs. 4.3%, P=0.035, respectively). The QoL was better after TLDG than after LADG regarding emotional functioning at 6 months, pain at 3 months, anxiety at 3 and 6 months, and body image at 3 and 6 months (all P<0.05). However, these QoL differences were resolved at 1 year. Conclusions: The KLASS-07 trial confirmed that TLDG is not different from LADG in terms of postoperative complications but has the advantages to reduce ileus and pulmonary complications. TLDG can be a good option to offer better QoL in terms of pain, body image, emotion, and anxiety at 3–6 months.

22 September 2023 in International Journal of Surgery
Verified
Journal Article
Open access
SPShin-Hoo Park
Shin-Hoo Park
HHHoon Hur
Hoon Hur
JPJong-Hyun Park
Jong-Hyun Park
CLChang-Min Lee
Chang-Min Lee
YSYoung-Gil Son
Young-Gil Son
Sungsoo ParkSungsoo Park
Sungsoo Park
Backgrounds: This study aimed to compare the incidence of bile reflux, quality of life (QoL), and nutritional status among Billroth II (BII), Billroth II with Braun anastomosis (BII-B), and Roux-en-Y (RY) reconstruction after laparoscopic distal gastrectomy (LDG). Materials and methods: We reviewed the prospective data of 397 patients from a multicentre database who underwent LDG for gastric cancer between 2018 and 2020 at 20 tertiary teaching hospitals in Korea. Postoperative endoscopic findings, QoL surveys using the European Organization for Research and Treatment of Cancer questionnaire (C30 and STO22), and nutritional and surgical outcomes were compared among groups. Results: In endoscopic findings, bile reflux was the lowest in the RY group (n=67), followed by the BII-B (n=183) and BII groups (n=147) at 1 year (3.0 vs. 67.8 vs. 84.4%, all P<0.05). The anti-reflux capability of BII-B was statistically better than that of BII, but not as perfect as that of RY. From the perspective of QoL, BII-B was not inferior to RY, but better than BII reconstruction in causing fewer STO22 reflux symptoms at 6 and 12 months. However, only RY caused fewer C30 nausea symptoms than BII at 6 and 12 months, but not BII-B. Nutritional status and morbidities were similar among the three groups, and the operative time did not differ between the BII-B and RY groups. Conclusions: BII-B cannot substitute for RY in preventing bile reflux, shortening the operative time, or reducing morbidities. Regarding short-term QoL, BII-B was sufficient to reduce STO22 reflux symptoms but failed to reduce C30 nausea symptoms postoperatively.

15 November 2023 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
DLDong Hui Lee
Dong Hui Lee
IJIn Ho Jeong
In Ho Jeong
BJBo Gun Jang
Bo Gun Jang
Background: The Wnt signaling pathway regulates crucial cellular processes, including stem cell development and tissue repair. Dysregulation of this pathway, particularly β-catenin stabilization, is linked to colorectal carcinoma and other tumors. Axin2, a critical component in the pathway, plays a role in β-catenin regulation. This study examines Axin2 expression in normal gastric mucosa and various gastric pathologies.Methods: Formalin-fixed and paraffin-embedded tissue samples from normal stomach, gastritis, intestinal metaplasia (IM), and gastric carcinoma were collected. Axin2 and β-catenin expression were evaluated using RNA in situ hybridization and immunohistochemistry, respectively. Histo-scores (H-scores) were calculated to quantify expression levels of Axin2. Associations between Axin2 expression and clinicopathological variables were examined.Results: Axin2 expression was examined in normal stomach, gastritis, and IM tissues. Axin2 expression was mainly observed in the surface and isthmus areas in the normal stomach and gastritis, whereas Axin2 expression was markedly higher at the bases of IM. Axin2 H-scores were significantly elevated in IM (mean ± standard deviation [SD], 87.0 ± 38.9) compared to normal (mean ± SD, 18.0 ± 4.5) and gastritis tissues (mean ± SD, 33.0 ± 18.6). In total, 30% of gastric carcinomas showed higher Axin2 expression. Axin2 expression did not have significant associations with age, sex, Lauren classification, histological differentiation, invasion depth, and lymph node metastasis. However, a strong positive correlation was observed between Axin2 and nuclear β-catenin in gastric carcinomas (p < .001).Conclusions: Axin2 expression was significantly increased in IM compared to normal and gastritis cases. In addition, Axin2 showed a strong positive association with nuclear β-catenin expression in gastric carcinomas, demonstrating a close relationship with abnormal Wnt/β-catenin signaling pathway.